Lakefront Biotherapeutics American Depositary Shares
LKFT
77 hedge funds and large institutions have $932M invested in Lakefront Biotherapeutics American Depositary Shares in 2017 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 27 increasing their positions, 26 reducing their positions, and 8 closing their positions.
100% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 8
12% more call options, than puts
Call options by funds: $634K | Put options by funds: $564K
12% more funds holding
Funds holding: 69 → 77 (+8)
4% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 26
0.32% less ownership
Funds ownership: 19.83% → 19.51% (-0.32%)
9% less capital invested
Capital invested by funds: $1.03B → $932M (-$95.2M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$18.6M |
| 2 |
Jane Street
New York
|
+$6.05M |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$5.97M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$5.09M |
| 5 |
Millennium Management
New York
|
+$4.29M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$27.6M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$12.3M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$7.03M |
| 4 |
BCPEM
Bain Capital Public Equity Management
Boston,
Massachusetts
|
-$4.28M |
| 5 |
OMC
Old Mission Capital
Chicago,
Illinois
|
-$3.9M |
LKFT Hedge Fund Activity: Q4 2017 in Review
77 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in Lakefront Biotherapeutics American Depositary Shares (LKFT) for Q4 2017, worth a combined $932M — down 9.3% from $1.03B a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new LKFT positions and 8 closed out — a net gain of 8 holders — while 27 added to existing stakes and 26 trimmed.
The largest buyer was BlackRock, adding an estimated $18.6M. The largest seller was Fidelity Investments, cutting an estimated $27.6M.
- 77 institutional investors held Lakefront Biotherapeutics American Depositary Shares (LKFT) as of Q4 2017, up from 69 in Q3 2017.
- Funds reported $932M of Lakefront Biotherapeutics American Depositary Shares stock for Q4 2017, down 9.3% quarter-over-quarter.
- 16 funds opened new Lakefront Biotherapeutics American Depositary Shares positions in Q4 2017 and 8 closed out, a net change of +8 holders.
- The largest Lakefront Biotherapeutics American Depositary Shares buyer in Q4 2017 was BlackRock, an estimated $18.6M added.
- The largest Lakefront Biotherapeutics American Depositary Shares seller in Q4 2017 was Fidelity Investments, an estimated $27.6M sold.
Based on aggregated 13F filings for Q4 2017.